Collectively, our data indicate a role for DNGR-1 in promoting cross-presentation of tumor antigens in the sGsn-deficient background, which leads to priming of anti-tumor CD8+ T cells that mediate cancer rejection. This evidence concerns the gene CLEC9A and neoplasm.